$RFL Cashflow Statement | Understand Stock

$RFL

$1.21 -$0.03 (2.42%) Close

$RFL Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Jul 31, 2025	FY2024 12 months to Jul 31, 2024	FY2023 12 months to Jul 31, 2023	FY2022 12 months to Jul 31, 2022	FY2021 12 months to Jul 31, 2021
Operating activities
Consolidated net loss
Less: Income (loss) from discontinued operations
Less: Income from discontinued operations
Loss from continuing operations
Adjustments to reconcile consolidated net loss to net cash used in operating activities
Deferred income taxes
Net unrealized (gain) loss on investments - Hedge Funds
Impairment of equity method investment of Altira
Realized loss on available-for-sale securities
Depreciation and amortization
Loss (gain) on sale of property and equipment
Net unrealized gain on investment - Hedge Funds
Net unrealized gain on investments - Hedge Funds
Unrealized gain in equity investments - Cyclo Therapeutics Inc.
Impairment of cost method investment - Cornerstone Pharmaceuticals
Impairment – Altira
Provision for loss on receivable from Cornerstone Pharmaceuticals pursuant to line of credit
Equity in loss (earnings) of RP Finance
Equity in loss of RP Finance
Equity in loss of Day Three Labs Inc.
Provision for losses on related party receivables
Realized loss on investment in equity securities
Realized gain on available-for-sale securities
Amortization of discount on available-for-sale securities
Loss on initial investment in Day Three upon acquisition
Loss on impairment of goodwill
Realized gain on equity investments - Cyclo
Unrealized loss (gain) on equity investments - Cyclo
Recovery of receivables from Cornerstone
In-process research and development expense
Unrealized loss (gain) on convertible notes receivable, due from Cyclo
Gain on dissolution of a business
Equity in loss of Day Three
Change in deferred income taxes
Credit loss expense
Impairment of investments - Other Pharmaceuticals
Realized gain in equity investments - Cyclo
Unrealized gain in equity investments - Cyclo
Unrealized gain on convertible notes receivable, due from Cyclo
Stock-based compensation
Amortization of debt issuance costs
Gain on DTLM Sale Transactions

Change in assets and liabilities, net of effects from acquisitions:
Trade accounts receivable
Interest receivable
Inventory
Prepaid expenses and other current assets
Prepaid clinical costs (current and non-current)
Other receivables
Other assets
Accounts payable and accrued expenses
Other current liabilities
Due from related parties
Due to related parties
Due from Cornerstone Pharmaceuticals
Accrued expenses, noncurrent
Convertible notes payable
Other liabilities
Net cash used in continuing operations
Net cash used in discontinued operations

Net cash used in operating activities
Investing activities
(Purchases) dispositions of property and equipment
Payment to Cornerstone Pharmaceuticals pursuant to Line of Credit
Purchase of property and equipment
Proceeds from sale of property and equipment
Purchases of available-for-sale securities
Proceeds from the sale and maturities of available-for-sale securities
Proceeds from Day Three patent sale
Purchase of intangible assets
Proceeds from sales of equity securities
Issuance of Convertible Notes, Due from Cyclo
Issuance of convertible note receivable, related party
Purchase of Investment in Day Three
Issuance of Convertible notes receivable, due from Cyclo
Payments for Convertible notes receivable, due from Cyclo
Purchases of equity securities
Payment to fund RP Finance Line of Credit
Investment in Altira
Purchase of Investment in Day Three Labs Inc.
Investment in Rafael Pharmaceuticals
Purchase of Investment in Cyclo Therapeutics Inc.
Purchase of investments in Cyclo
Issuance of convertible note receivable
Issuance of Day Three Promissory Notes
Proceeds from investments - Other Pharmaceuticals
Cash paid in Cyclo Merger, net of cash acquired
Cash acquired in acquisition of Day Three, net of cash payments
Cash acquired in the Cornerstone Acquisition, net of cash payments
Proceeds from hedge funds
Net cash used in investing activities of continuing operations
Proceeds from sale of 520 Property - discontinued operations
Payment of transaction costs for sale of 520 Property - discontinued operations
Purchases of available-for-sale securities
Proceeds from maturities of available-for-sale securities
Proceeds from sale of building
Net cash provided by investing activities of discontinued operations
Net cash provided by (used in) investing activities

Financing activities
Contribution from noncontrolling interest of consolidated entity
Proceeds from exercise of options
Proceeds from exercise of warrants
Proceeds from issuance of note payable
Payment of debt issuance costs
Principal payments on installment note payable
Net cash used in financing activities of continuing operations
Payment of Note Payable in connection with sale of 520 Property - discontinued operations
Net cash used in financing activities of discontinued operations
Payments for taxes related to shares withheld for employee taxes
Purchases of treasury stock
Proceeds from issuance of common stock in Rights Offering, net of transaction costs
Proceeds from issuance of common stock from related party
Payment of transaction costs incurred in connection with sale of common stock
Proceeds from sale of Rafael Medical Devices membership units
Net cash provided by (used in) financing activities

Effect of exchange rate changes on cash, cash equivalents and restricted cash
Net increase (decrease) in cash, cash equivalents and restricted cash
Cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents, beginning of year
Cash and cash equivalents, end of year
Common shares issued for payment of purchase price for Altira equity
Restricted cash
Total cash, cash equivalents and restricted cash shown in statement of cash flows
Non-cash supplemental disclosure
Acquisition of additional ownership interest in LipoMedix
Cash and cash equivalents
Restricted cash
Total cash and cash equivalents and restricted cash shown in statement of cash flows
Fair value of Class B common stock issued as consideration in Cyclo Merger
Fair value of Rollover Options issued as consideration in Cyclo Merger
Fair value of Replacement Warrants issued as consideration in Cyclo Merger
Fair value of Cyclo Convertible notes receivable included as consideration in Cyclo Merger
Transaction costs related to the Rights Offering included in accounts payable
Conversion of RFL Line of Credit into Cornerstone Common Stock
Conversion of 2023 Promissory Note into Cornerstone Common Stock
Recognition of noncontrolling interest in the Cornerstone Acquisition
Noncash consideration received in exchange for equipment
Recognition of noncontrolling interest in the RP Finance Consolidation, net of elimination
Gain on RP Finance Consolidation recorded as an adjustment to additional paid-in capital due to related party nature of transaction, net of elimination
Non-cash consideration received in exchange for equipment
Conversion of Convertible notes receivable, due from Cyclo into common stock
Elimination of principal and accrued interest on the Day Three Promissory Notes included in consideration for acquisition of Day Three
Convertible note receivable received in exchange for Day Three Labs Manufacturing assets

Comments